Hyperlipidemia Drugs Market Size & Share, Sector / Industry Report & Analysis 2020, & Forecast 2021-2026 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Global Hyperlipidemia Drugs Market


The global Hyperlipidemia Drugs market size is projected to reach US$ 24.23 billion by 2026, from US$ 21.14 billion in 2020, at a CAGR of 2.3% during 2021-2026. Introduction of new guidelines that redefined at-risk patient groups and emergence of novel drug classes promising better efficacy and safety levels are among key factors stoking market growth.

Hyperlipidemia is caused by elevation in blood lipid levels and can be classified into two types - primary and secondary. Primary or familial hyperlipidemia is caused by genetic factors, whereas secondary hyperlipidemia is caused by environmental factors. Statins are the first line of therapy for this disorder.

A total cholesterol level of 170mg/dl or less is acceptable, 170 to 199mg/dl is borderline, and 200mg/dl or more is high. According to the American Heart Association, cholesterol levels steadily increase after 20 years of age. They normally decline after the age of 70 in women and 60 in men. Additionally, women of all ages tend to have about 10mg/dl higher mean HDL-C levels as compared to men of all ages.

The market is anticipated to grow modestly during the forecast period. Some of the factors anticipated to augment the market are emergence of new drug classes for the benefit of nonstatin users, increase in number of statin users, and guidelines recommending use of antihyperlipidemics to lower risk of cardiovascular diseases (CVD).

Hyperlipidemia guidelines in the U.S. are playing an imperative role in the growth of the market as they address dosage regimen of statins, which include patients aged 21 years and above suffering from risk of developing Atherosclerotic Cardiovascular Disease (ASCVD). As a result, target population for statins is expanding to other comorbidities of high cholesterol and triglyceride levels.

Most antihyperlipidemic drugs have minor adverse effects. However, some drugs are likely to cause serious adverse effects such as liver damage or type 2 diabetes. Drug classes such as CETP inhibitors have been withdrawn or discontinued even in the later stages of trials due to adverse effects or failure to achieve satisfactory results. Risks associated with antihyperlipidemics pose a major challenge to their entry into the market.

High cholesterol in blood increases risk of myocardial infarction and stroke. Thus, hypercholesterolemia increases susceptibility to CVD. Hyperlipidemia is associated with other major comorbidities such as diabetes type II and chronic kidney disease.

According to the World Health Organization (WHO), hypercholesterolemia is estimated to result in more than 2.6 million deaths each year. Almost 37.0% adults in the U.S. have high LDL-C levels. Yet, lesser than 50.0% patients receive any form of treatment and approximately 33.0% of patients undergoing treatment are unable to achieve normal lipid levels.

Market Segmentation, Outlook & Viewpoint: Global Hyperlipidemia Drugs Market

Drug Class Market Segmentation & Outlook (Revenue, USD Million, 2016 - 2022)

  
Statins
  
Bile Acid Sequestrants
  
Cholesterol Absorption Inhibitors
  
Fibric Acid Derivatives
  
PCSK9 Inhibitors
  
Combination
  
Miscellaneous

Key Players, Recent Developments & Regional Insights: Global Hyperlipidemia Drugs Market

On the basis of drug class, the market has been segmented into statins, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, PCSK9 inhibitors, combination, and miscellaneous antihyperlipidemic agents. Miscellaneous antihyperlipidemic drug class includes omega-3 fatty acids, nicotinic acids, lomitapide, mipomersen, and bempedoic acid.

In 2016, statins led the hyperlipidemia drugs market with a share of approximately 30.0%. However, the market for statins is projected to decline at a CAGR of more than 7.5% during the forecast period due to arrival of more effective therapies such as PCSK9 inhibitors and bempedoic acid. These new drug classes are poised to target statin-resistant as well as statin-intolerant population. High adverse effects associated with use of upcoming drugs is expected to negatively impact the sales of statins

Miscellaneous antihyperlipidemic agents include niacin, omega-3 fatty acids, MTP-inhibitors, apoB-100 inhibitors, and more recent agents such as ACL-inhibitors. This drug class is estimated to witness healthy growth over the forecast period due to improved safety and efficacy profiles of pipeline drugs and increase in adoption among end users. Higher efficacy of this drug class compared to statins and its ability to reduce the risk of CVD during ongoing clinical trials are among factors anticipated to boost its adoption among nonstatin users.

Regional Insights

Europe was the leading revenue contributor in the global arena in 2016, representing more than half of the overall market. The region is likely to maintain its dominance until 2022. This can be attributed to the high prevalence of hypercholesterolemia in this region. It was followed by North America with about 35.50% revenue share.

Japans hyperlipidemia market has fewer growth opportunities owing to non-availability of key revenue-generating products such as bempedoic acid. Thus, its market share is projected to decline by more than 1.5% by 2022.

Hyperlipidemia Drugs Market Share Insights

Some of the key players operating in the market are AstraZeneca; Merck & Co., Inc.; Pfizer, Inc.; DAIICHI SANKYO COMPANY, LIMITED; Amgen, Inc.; and Sanofi. Several companies, such as Esperion Therapeutics and CJ Healthcare, have promising drugs in the pipeline.
Various companies, such as AstraZeneca; Merck & Co., Inc.; and Daiichi Sankyo, are poised to lose significant share due to patent expiration of drugs offered by them, which include Crestor, Zetia, Vytorin, and Welchol. Amgen and Sanofi are expected to witness healthy growth due to increase in usage of PCSK9 inhibitors such as Repatha and Praluent.

Key Insights Covered: Global Hyperlipidemia Drugs Market

1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Hyperlipidemia Drugs industry.
2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Hyperlipidemia Drugs industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Hyperlipidemia Drugs industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Hyperlipidemia Drugs industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Hyperlipidemia Drugs industry.

Research Methodology: Global Hyperlipidemia Drugs Market

  
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other